Canakinumab: un anticuerpo monoclonal prometedor en el tratamiento de enfermedades cardiovasculares
Canakinumab: a promising monoclonal antibody in the treatment of cardiovascular diseases
Leído
5691
Vecesse ha leído el artículo
3761
Total PDF
1930
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 19 | 11 | 30 |
| 2025 11 | 31 | 43 | 74 |
| 2025 10 | 15 | 18 | 33 |
| 2025 9 | 13 | 8 | 21 |
| 2025 8 | 20 | 17 | 37 |
| 2025 7 | 31 | 13 | 44 |
| 2025 6 | 24 | 6 | 30 |
| 2025 5 | 21 | 7 | 28 |
| 2025 4 | 21 | 13 | 34 |
| 2025 3 | 21 | 11 | 32 |
| 2025 2 | 14 | 17 | 31 |
| 2025 1 | 17 | 9 | 26 |
| 2024 12 | 7 | 7 | 14 |
| 2024 11 | 25 | 7 | 32 |
| 2024 10 | 11 | 8 | 19 |
| 2024 9 | 13 | 10 | 23 |
| 2024 8 | 19 | 4 | 23 |
| 2024 7 | 6 | 9 | 15 |
| 2024 6 | 16 | 14 | 30 |
| 2024 5 | 16 | 24 | 40 |
| 2024 4 | 7 | 7 | 14 |
| 2024 3 | 14 | 16 | 30 |
| 2024 2 | 9 | 11 | 20 |
| 2024 1 | 8 | 13 | 21 |
| 2023 12 | 16 | 18 | 34 |
| 2023 11 | 10 | 21 | 31 |
| 2023 10 | 18 | 17 | 35 |
| 2023 9 | 12 | 4 | 16 |
| 2023 8 | 17 | 7 | 24 |
| 2023 7 | 23 | 47 | 70 |
| 2023 6 | 17 | 6 | 23 |
| 2023 5 | 26 | 34 | 60 |
| 2023 4 | 11 | 8 | 19 |
| 2023 3 | 19 | 13 | 32 |
| 2023 2 | 14 | 8 | 22 |
| 2022 1 | 7 | 12 | 19 |
| 2022 12 | 10 | 13 | 23 |
| 2022 11 | 21 | 14 | 35 |
| 2022 10 | 14 | 13 | 27 |
| 2022 9 | 10 | 12 | 22 |
| 2022 8 | 11 | 14 | 25 |
| 2022 7 | 9 | 10 | 19 |
| 2022 6 | 8 | 15 | 23 |
| 2022 5 | 10 | 33 | 43 |
| 2022 4 | 8 | 12 | 20 |
| 2022 3 | 7 | 20 | 27 |
| 2022 2 | 32 | 8 | 40 |
| 2021 1 | 25 | 23 | 48 |
| 2021 12 | 11 | 15 | 26 |
| 2021 11 | 17 | 21 | 38 |
| 2021 10 | 21 | 18 | 39 |
| 2021 9 | 23 | 22 | 45 |
| 2021 8 | 10 | 5 | 15 |
| 2021 7 | 13 | 10 | 23 |
| 2021 6 | 21 | 19 | 40 |
| 2021 5 | 25 | 16 | 41 |
| 2021 4 | 72 | 20 | 92 |
| 2021 3 | 23 | 25 | 48 |
| 2021 2 | 27 | 19 | 46 |
| 2020 1 | 12 | 28 | 40 |
| 2020 12 | 17 | 27 | 44 |
| 2020 11 | 9 | 20 | 29 |
| 2020 10 | 12 | 32 | 44 |
| 2020 9 | 18 | 21 | 39 |
| 2020 8 | 13 | 25 | 38 |
| 2020 7 | 27 | 14 | 41 |
| 2020 6 | 16 | 13 | 29 |
| 2020 5 | 13 | 7 | 20 |
| 2020 4 | 14 | 8 | 22 |
| 2020 3 | 12 | 48 | 60 |
| 2020 2 | 20 | 23 | 43 |
| 2020 1 | 15 | 24 | 39 |
| 2019 12 | 25 | 27 | 52 |
| 2019 11 | 12 | 13 | 25 |
| 2019 10 | 24 | 8 | 32 |
| 2019 9 | 22 | 22 | 44 |
| 2019 8 | 11 | 12 | 23 |
| 2019 7 | 9 | 31 | 40 |
| 2019 6 | 37 | 80 | 117 |
| 2019 5 | 73 | 168 | 241 |
| 2019 4 | 39 | 101 | 140 |
| 2019 3 | 6 | 23 | 29 |
| 2019 2 | 11 | 27 | 38 |
| 2019 1 | 4 | 27 | 31 |
| 2018 12 | 10 | 27 | 37 |
| 2018 11 | 8 | 45 | 53 |
| 2018 10 | 14 | 38 | 52 |
| 2018 9 | 17 | 29 | 46 |
| 2018 8 | 3 | 79 | 82 |
| 2018 7 | 5 | 79 | 84 |
| 2018 6 | 10 | 98 | 108 |
| 2018 5 | 2 | 98 | 100 |
| 2018 4 | 3 | 80 | 83 |
| 2018 3 | 7 | 65 | 72 |
| 2018 2 | 4 | 55 | 59 |
| 2018 1 | 4 | 52 | 56 |
| 2017 12 | 9 | 44 | 53 |
| 2017 11 | 7 | 79 | 86 |
| 2017 10 | 8 | 88 | 96 |
| 2017 9 | 4 | 111 | 115 |
| 2017 8 | 14 | 77 | 91 |
| 2017 7 | 8 | 52 | 60 |
| 2017 6 | 13 | 60 | 73 |
| 2017 5 | 17 | 17 | 34 |
| 2017 4 | 19 | 66 | 85 |
| 2017 3 | 12 | 113 | 125 |
| 2017 2 | 14 | 79 | 93 |
| 2016 1 | 8 | 32 | 40 |
| 2016 12 | 21 | 24 | 45 |
| 2016 11 | 14 | 41 | 55 |
| 2016 10 | 28 | 33 | 61 |
| 2016 9 | 9 | 37 | 46 |
| 2016 8 | 17 | 19 | 36 |
| 2016 7 | 4 | 13 | 17 |
| 2016 6 | 8 | 22 | 30 |
| 2016 5 | 7 | 28 | 35 |
| 2016 4 | 5 | 26 | 31 |
| 2016 3 | 8 | 30 | 38 |
| 2016 2 | 5 | 22 | 27 |
| 2015 1 | 10 | 23 | 33 |
| 2015 12 | 5 | 17 | 22 |
| 2015 11 | 9 | 25 | 34 |
| 2015 10 | 12 | 25 | 37 |
| 2015 9 | 8 | 17 | 25 |
| 2015 8 | 3 | 9 | 12 |
| 2015 7 | 5 | 5 | 10 |
| 2015 6 | 2 | 10 | 12 |
| 2015 5 | 4 | 8 | 12 |
| 2015 4 | 7 | 13 | 20 |
| 2015 3 | 5 | 19 | 24 |
| 2015 2 | 5 | 13 | 18 |
| 2015 1 | 4 | 1 | 5 |
| 2014 12 | 6 | 7 | 13 |
| 2014 11 | 5 | 3 | 8 |
| 2014 10 | 5 | 3 | 8 |
| 2014 8 | 2 | 1 | 3 |
Mostrar todo